表紙
市場調査レポート

中枢神経系疾患における被験者募集:統合失調症治験に最大数の被験者

Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia

発行 GBI Research 商品コード 212665
出版日 ページ情報 英文 97 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
中枢神経系疾患における被験者募集:統合失調症治験に最大数の被験者 Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
出版日: 2011年09月01日 ページ情報: 英文 97 Pages
概要

中枢神経系疾患の治験数は過去数年増加しています。2000〜2009年には統合失調症において最大の被験者数で治験が実施されました。特に第3相が最大となりました。

当レポートでは、2000〜2009年に開始された全治験を分析し、アルツハイマー病、パーキンソン病、てんかん、統合失調症、鬱病の主要な5つの適応についてそれぞれの治験動向、ブラジル、インド、中国の動向、平均被験者数などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 中枢神経系疾患における被験者募集:イントロダクション

第3章 治験概要

  • 治療分野別治験シェア
  • 2005〜2010年の製薬会社別治験
  • CNSにおける治験と被験者募集

第4章 アルツハイマー病の治験と被験者募集

  • イントロダクション
  • 治験
    • 開発段階別
    • 治験依頼者別
    • 地域別
    • 年度別
  • 有病人口(2010〜2017年)
    • ブラジル
    • インド
    • 中国
  • 被験者募集
  • 治験当たりの平均被験者数

第5章 パーキンソン病の治験と被験者募集

  • イントロダクション
  • 治験
    • 開発段階別
    • 治験依頼者別
    • 地域別
    • 年度別
  • 有病人口(2010〜2017年)
    • ブラジル
    • インド
    • 中国
  • 被験者募集
  • 治験当たりの平均被験者数

第6章 てんかんの治験と被験者募集

  • イントロダクション
  • 治験
    • 開発段階別
    • 治験依頼者別
    • 地域別
    • 年度別
  • 有病人口(2010〜2017年)
    • ブラジル
    • インド
    • 中国
  • 被験者募集
  • 治験当たりの平均被験者数

第7章 統合失調症の治験と被験者募集

  • イントロダクション
  • 治験
    • 開発段階別
    • 治験依頼者別
    • 地域別
    • 年度別
  • 有病人口(2010〜2017年)
    • ブラジル
    • インド
    • 中国
  • 被験者募集
  • 治験当たりの平均被験者数

第8章 鬱病の治験と被験者募集

  • イントロダクション
  • 治験
    • 開発段階別
    • 治験依頼者別
    • 地域別
    • 年度別
  • 有病人口(2010〜2017年)
    • ブラジル
    • インド
    • 中国
  • 被験者募集
  • 治験当たりの平均被験者数

第9章 付録

図表

目次
Product Code: GBIHC119MR

Abstract

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia”. It gives a robust idea about the patient recruitment status by geography, by sponsor company, and by year for all the major CNS indications. Furthermore, the report provides profiles of prevalence with forecast data up to 2017 for all the major CNS indications. The major indications covered in the report are Alzheimer's disease, Parkinson's disease, Epilepsy, Schizophrenia and Depression. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research found that the highest number of trials was conducted in schizophrenia, which corresponds to the highest levels of patient recruitment for the period 2000-2009, for trials which were industry sponsored with completed status. Within the CNS market, the Alzheimer's and Parkinson's disease sectors have been identified as the fastest growing sectors. In terms of reimbursement, countries like Germany, France and Canada have been identified as having the most robust and patient-friendly regulations for CNS therapeutics. The central nervous system is a complex and sophisticated system that regulates and co-ordinates the basic functions and activities of the human body. The human central nervous system consists of the brain, spinal cord and the neural network connecting these to the body. Owing to its complexity and intricacies, the CNS is vulnerable to various complications and disorders. Disorders within the CNS are primarily associated with the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system and the neuromuscular network, including the muscles. A substantial portion of CNS disorders can be grouped under neurodegenerative disorders such as Alzheimer's, which are primarily associated with the deterioration or break down of cerebral and spinal cells. Other diseases associated with the CNS include psychiatric or mental disorders such as Attention Deficit Hyperactivity Disorder (ADHD). These disorders are related to individuals' psychological or behavioral patterns, and are thought to cause distress or disabilities that are not expected as part of normal development. Other major neurological disorders include epilepsy, pain and sleep related complications such as migraine and insomnia.

Scope

The report analyzes the clinical trial recruitment trends of the pharmaceutical companies for various neurology trials.

Its scope includes:

  • Insight on Clinical Trials conducted for major indications of neurology such as Alzheimer's disease, Parkinson's disease, Epilepsy, Schizophrenia and Depression from 2000-2009.
  • The status of patient recruitment by geography, Sponsor Company, year and stage of development.
  • Analysis of the average number of patients recruited per trial for major indications per year.
  • Analysis of the average number of patients recruited per trial for major indications by stage of development.
  • The prevalence population in India, China and Brazil for all major indications from 2010-2017.

Reasons to buy

The report will enhance your decision making capability.

It will allow you to:

  • Identify and understand the status of clinical trials conducted for major neurology indications from 2000-2009.
  • Build understanding of patient recruitment status by geography, Sponsor Company, year and stage of development.
  • Identify the prevalence population for the major indications up to 2017.
  • Identify the average number of patients recruited by stage of development and across years for all major indications.
  • Identify the indication in which the highest number of trials is conducted and the highest number of patients recruited.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Clinical Trial Recruitment in Central Nervous System Disorders - Introduction

  • 2.1. GBI Research Report Guidance

3. Clinical Trials Overview

  • 3.1. Clinical Trials Share by Therapeutic Area
  • 3.2. Clinical Trials by Pharmaceutical Companies, 2005-2010
  • 3.3. Clinical Trials and Patient Recruitment in CNS

4. Clinical Trials and Patient Recruitment for Alzheimer's Disease

  • 4.1. Introduction
  • 4.2. Clinical Trials for Alzheimer's Disease
    • 4.2.1. Number of Clinical Trials by Stage of Development
    • 4.2.2. Number of Clinical Trials by Sponsor
    • 4.2.3. Number of Clinical Trials by Geography
    • 4.2.4. Number of Clinical Trials by Year
  • 4.3. Prevalence Population for Alzheimer's disease (2010-2017)
    • 4.3.1. Brazil
    • 4.3.2. India
    • 4.3.3. China
  • 4.4. Patient Recruitment for Alzheimer's Disease
    • 4.4.1. Number of Patients Recruited by Stage of Development
    • 4.4.2. Number of Patients Recruited by Sponsor
    • 4.4.3. Number of Patients Recruited by Geography
    • 4.4.4. Number of Patients Recruited Per Year
  • 4.5. Average Number of Patients Recruited Per Trial
    • 4.5.1. Average Number of Patients Recruited Per Trial by Stage of Development
    • 4.5.2. Average Number of Patients Recruited Per Trial Per Year

5. Clinical Trials and Patient Recruitment for Parkinson's Disease

  • 5.1. Introduction
  • 5.2. Clinical Trials for Parkinson's Disease
    • 5.2.1. Number of Clinical Trials by Stage of Development
    • 5.2.2. Number of Clinical Trials by Sponsor
    • 5.2.3. Number of Clinical Trials by Geography
    • 5.2.4. Number of Clinical Trials by Year
  • 5.3. Prevalence Population for Parkinson's disease (2010-2017)
    • 5.3.1. Brazil
    • 5.3.2. India
    • 5.3.3. China
  • 5.4. Patient Recruitment for Parkinson's Disease
    • 5.4.1. Number of Patients Recruited by Stage of Development
    • 5.4.2. Number of Patients Recruited by Sponsor
    • 5.4.3. Number of Patients Recruited by Geography
    • 5.4.4. Number of Patients Recruited Per Year
  • 5.5. Average Number of Patients Recruited Per Trial
    • 5.5.1. Average Number of Patients Recruited Per Trial by Stage of Development
    • 5.5.2. Average Number of Patients Reruited per Trial per Year

6. Clinical Trials and Patient Recruitment for Epilepsy

  • 6.1. Introduction
  • 6.2. Clinical Trials for Epilepsy
    • 6.2.1. Number of Clinical Trials by Stage of Development
    • 6.2.2. Number of Clinical Trials by Sponsor
    • 6.2.3. Number of Clinical Trials by Geography
    • 6.2.4. Number of Clinical Trials by Year
  • 6.3. Prevalence Population for Epilepsy (2010-2017)
    • 6.3.1. Brazil
    • 6.3.2. India
    • 6.3.3. China
  • 6.4. Patient Recruitment for Epilepsy
    • 6.4.1. Number of Patients Recruited by Stage of Development
    • 6.4.2. Number of Patients Recruited by Sponsor
    • 6.4.3. Number of Patients Recruited by Geography
    • 6.4.4. Number of Patients Recruited Per Year
  • 6.5. Average Number of Patients Recruited Per Trial
    • 6.5.1. Average Number of Patients Recruited Per Trial by Stage of Development
    • 6.5.2. Average Number of Patients Recruited Per Trial Per Year

7. Clinical Trials and Patient Recruitment for Schizophrenia

  • 7.1. Introduction
  • 7.2. Clinical Trials for Schizophrenia
    • 7.2.1. Number of Clinical Trials by Stage of Development
    • 7.2.2. Number of Clinical Trials by Sponsor
    • 7.2.3. Number of Clinical Trials by Geography
    • 7.2.4. Number of Clinical Trials by Year
  • 7.3. Prevalence Population for Schizophrenia (2010-2017)
    • 7.3.1. Brazil
    • 7.3.2. India
    • 7.3.3. China
  • 7.4. Patient Recruitment for Schizophrenia
    • 7.4.1. Number of Patients Recruited by Stage of Development
    • 7.4.2. Number of Patients Recruited by Sponsor
    • 7.4.3. Number of Patients Recruited by Geography
    • 7.4.4. Number of Patients Recruited Per Year
  • 7.5. Average Number of Patients Recruited Per Trial
    • 7.5.1. Average Number of Patients Recruited Per Trial by Stage of Development
    • 7.5.2. Average Number of Patients Recruited Per Trial Per Year

8. Clinical Trials and Patient Recruitment for Depression

  • 8.1. Introduction
  • 8.2. Clinical Trials for Depression
    • 8.2.1. Number of Clinical Trials by Stage of Development
    • 8.2.2. Number of Clinical Trials by Sponsor
    • 8.2.3. Number of Clinical Trials by Geography
    • 8.2.4. Number of Clinical Trials by Year
  • 8.3. Prevalence Population for Depression (2010-2017)
    • 8.3.1. Brazil
    • 8.3.2. India
    • 8.3.3. China
  • 8.4. Patient Recruitment for Depression
    • 8.4.1. Number of Patients Recruited by Stage of Development
    • 8.4.2. Number of Patients Recruited by Sponsor
    • 8.4.3. Number of Patients Recruited by Geography
    • 8.4.4. Number of Patients Recruited Per Year
  • 8.5. Average Number of Patients Recruited Per Trial
    • 8.5.1. Average Number of Patients Recruited per Trial by Stage of Development
    • 8.5.2. Average Number of Patients Recruited per Trial per Year

9. Clinical Trials Recruitment in Central Nervous System: Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Research Methodology
    • 9.3.1. Coverage
    • 9.3.2. Secondary Research
    • 9.3.3. Primary Research
    • 9.3.4. Expert Panel Validation
    • 9.3.5. Section-wise methodology
  • 9.4. Contact Us
  • 9.5. Disclaimer
  • 9.6. Sources

List of Tables

  • Table 1: Clinical Trial Recruitment in CNS, Global, Ongoing Trials by Therapeutic Area, 2005-2010
  • Table2: Clinical Trial Recruitment in CNS, Asia, Ongoing Trials by Therapeutic Area, 2005-2010
  • Table3: Clinical Trial Recruitment in CNS, Europe, Ongoing Trials by Therapeutic Area, 2005-2010
  • Table4: Clinical Trial Recruitment in CNS, Middle East, Ongoing Trials by Therapeutic Area, 2005-2010
  • Table5: Clinical Trial Recruitment in CNS, South and Central America, Ongoing Trials by Therapeutic Area, 2005-2010
  • Table6: Clinical Trial Recruitment in CNS, North America, Ongoing Trials by Therapeutic Area, 2005-2010
  • Table7: Clinical Trial Recruitment in CNS, Rest of World, Ongoing Trials by Therapeutic Area, 2005-2010
  • Table8: Clinical Trial Recruitment in CNS, Global, Clinical Trials by Pharmaceutical Companies, 2005-2010
  • Table9: Clinical Trial Recruitment in CNS, Global, Clinical Trials in Major Indications, 2000-2009
  • Table10: Clinical Trial Recruitment in CNS, Global, Total Number of Patients Recruited for Major Indications, 2000-2009
  • Table 11: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Clinical Trials by Phase, 2000-2009
  • Table 12: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Clinical Trials by Sponsor, 2000-2009
  • Table 13: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Clinical Trials by Geography, (%), 2000-2009
  • Table 14: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Clinical Trials per Year, 2000-2009
  • Table 15: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Prevalence Population, Brazil, (million) 2010-2017
  • Table 16: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Prevalence Population, India, (Million) 2010-2017
  • Table 17: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Prevalence Population, China, (Million) 2010-2017
  • Table 18: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Patients Recruited by Phase, 2000-2009
  • Table 19: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Patients Recruited by Sponsor, 2000-2009
  • Table 20: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Patients Recruited by Geography, (%), 2000-2009
  • Table 21: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Patients Recruited per Year, 2000-2009
  • Table 22: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2009
  • Table 23: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Average Number of Patients Recruited per Trial per Year, 2000-2009
  • Table 24: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Clinical Trials by Phase, 2000-2009
  • Table 25: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Clinical Trials by Sponsor, 2000-2009
  • Table 26: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Clinical Trials by Geography (%), 2000-2009
  • Table 27: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Clinical Trials per Year, 2000-2009
  • Table 28: Clinical Trial Recruitment in CNS, Parkinson's Disease, Prevalence Population, Brazil, (Million), 2010-2017
  • Table 29: Clinical Trial Recruitment in CNS, Parkinson's Disease, Prevalence Population, India, (Million), 2010-2017
  • Table 30: Clinical Trial Recruitment in CNS, Parkinson's Disease, Prevalence Population, China, (Million), 2010-2017
  • Table 31: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Patients Recruited by Phase, 2000-2009
  • Table 32: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Patients Recruited by Major Sponsors, 2000-2009
  • Table 33: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Patients Recruited by Geography (%), 2000-2009
  • Table 34: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Patients Recruited per Year, 2000-2009
  • Table 35: Clinical Trial Recruitment in CNS, Parkinson's Disease, Average Number of Patients Recruited by Stage of Development, 2000-2009
  • Table 36: Clinical Trial Recruitment in CNS, Parkinson's Disease, Average Number of Patients Recruited per Trial per Year, 2000-2009
  • Table 37: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Clinical Trials by Phase, 2000-2009
  • Table 38: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Clinical Trials by Major Sponsors, 2000-2009
  • Table 39: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Clinical Trials by Geography (%), 2000-2009
  • Table 40: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Clinical Trials per Year, 2000-2009
  • Table 41: Clinical Trial Recruitment in CNS, Epilepsy, Prevalence Population, Brazil, (Million), 2010-2017
  • Table 42: Clinical Trial Recruitment in CNS, Epilepsy, Prevalence Population, India, (Million), 2010-2017
  • Table 43: Clinical Trial Recruitment in CNS, Epilepsy, Prevalence Population, China, (Million), 2010-2017
  • Table 44: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Patients Recruited by Phase, 2000-2009
  • Table 45: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Patients Recruited by Major Sponsors, 2000-2009
  • Table 46: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Patients Recruited by Geography (%), 2000-2009
  • Table 47: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Patients Recruited per Year, 2000-2009
  • Table 48: Clinical Trial Recruitment in CNS, Epilepsy, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2009
  • Table 49: Clinical Trial Recruitment in CNS, Epilepsy, Average Number of Patients Recruited per Trial per Year, 2000-2009
  • Table 50: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Clinical Trials by Phase, 2000-2009
  • Table 51: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Clinical Trials by Major Sponsors, 2000-2009
  • Table 52: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Clinical Trials by Geography (%), 2000-2009
  • Table 53: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Clinical Trials per Year, 2000-2009
  • Table 54: Clinical Trial Recruitment in CNS, Schizophrenia, Prevalence Population, Brazil, (Million), 2010-2017
  • Table 55: Clinical Trial Recruitment in CNS, Schizophrenia, Prevalence Population, India, (Million), 2010-2017
  • Table 56: Clinical Trial Recruitment in CNS, Schizophrenia, Prevalence Population, China, (Million), 2010-2017
  • Table 57: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Patients Recruited by Phase, 2000-2009
  • Table 58: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Patients Recruited by Major Sponsors, 2000-2009
  • Table 59: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Patients Recruited by Geography (%), 2000-2009
  • Table 60: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Patients Recruited per Year, 2000-2009
  • Table 61: Clinical Trial Recruitment in CNS, Schizophrenia, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2009
  • Table 62: Clinical Trial Recruitment in CNS, Schizophrenia, Average Number of Patients Recruited per Trial per Year, 2000-2009
  • Table 63: Clinical Trial Recruitment in CNS, Depression, Total Number of Clinical Trials by Phase, 2000-2009
  • Table 64: Clinical Trial Recruitment in CNS, Depression, Total Number of Clinical Trials by Major Sponsors, 2000-2009
  • Table 65: Clinical Trial Recruitment in CNS, Depression, Total Number of Clinical Trials by Geography, (%), 2000-2009
  • Table 66: Clinical Trial Recruitment in CNS, Depression, Total Number of Clinical Trials per Year, 2000-2009
  • Table 67: Clinical Trial Recruitment in CNS, Depression, Prevalence Population, Brazil, (Million), 2010-2017
  • Table 68: Clinical Trial Recruitment in CNS, Depression, Prevalence Population, India, (Million), 2010-2017
  • Table 69: Clinical Trial Recruitment in CNS, Depression, Prevalence Population, China, (Million), 2010-2017
  • Table 70: Clinical Trial Recruitment in CNS, Depression, Total Number of Patients Recruited by Stage of Development, 2000-2009
  • Table 71: Clinical Trial Recruitment in CNS, Depression, Total Number of Patients Recruited by Major Sponsors, 2000-2009
  • Table 72: Clinical Trial Recruitment in CNS, Depression, Total Number of Patients Recruited by Geography, (%), 2000-2009
  • Table 73: Clinical Trial Recruitment in CNS, Depression, Total Number of Patients Recruited by Major Sponsors, 2000-2009
  • Table 74: Clinical Trial Recruitment in CNS, Depression, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2009
  • Table 75: Clinical Trial Recruitment in CNS, Depression, Average Number of Patients Recruited per Trial per Year, 2000-2009

List of Figures

  • Figure 1: Clinical Trial Recruitment in CNS, Global, Ongoing Trials by Therapeutic Area, 2005-2010
  • Figure 2: Clinical Trial Recruitment in CNS, Asia, Ongoing Trials by Therapeutic Area, 2005-2010
  • Figure 3: Clinical Trial Recruitment in CNS, Europe, Ongoing Trials by Therapeutic Area, 2005-2010
  • Figure 4: Clinical Trial Recruitment in CNS, Middle East, Ongoing Trials by Therapeutic Area, 2005-2010
  • Figure 5: Clinical Trial Recruitment in CNS, South and Central America, Ongoing Trials by Therapeutic Area, 2005-2010
  • Figure 6: Clinical Trial Recruitment in CNS, North America, Ongoing Trials by Therapeutic Area, 2005-2010
  • Figure 7: Clinical Trial Recruitment in CNS, Rest of World, Ongoing Trials by Therapeutic Area, 2005-2010
  • Figure 8: Clinical Trial Recruitment in CNS, Global, Clinical Trials by Pharmaceutical Companies, 2005-2010
  • Figure 9: Clinical Trial Recruitment in CNS, Global, Clinical Trials in Major Indications, 2000-2009
  • Figure 10: Clinical Trial Recruitment in CNS, Global, Total Number of Patients Recruited for Major Indications, 2000-2009
  • Figure 11: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Clinical Trials by Phase, 2000-2009
  • Figure 12: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Clinical Trials by Major Sponsor, 2000-2009
  • Figure 13: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Clinical Trials by Geography, (%), 2000-2009
  • Figure 14: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Clinical Trials per Year, 2000-2009
  • Figure 15: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Prevalence Population, Brazil, (million), 2010-2017
  • Figure 16: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Prevalence Population, India, (Million) 2010-2017
  • Figure 17: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Prevalence Population, China, (Million) 2010-2017
  • Figure 18: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Patients Recruited by Phase, 2000-2009
  • Figure 19: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Patients Recruited by Major Sponsors, 2000-2009
  • Figure 20: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Patients Recruited by Geography, (%), 2000-2009
  • Figure 21: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Total Number of Patients Recruited per Year, 2000-2009
  • Figure 22: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2009
  • Figure 23: Clinical Trial Recruitment in CNS, Alzheimer's Disease, Average Number of Patients Recruited per Trial per Year, 2000-2009
  • Figure 24: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Clinical Trials by Phase, 2000-2009
  • Figure 25: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Clinical Trials by Sponsor, 2000-2009
  • Figure 26: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Clinical Trials by Geography, (%), 2000-2009
  • Figure 27: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Clinical Trials per Year, 2000-2009
  • Figure 28: Clinical Trial Recruitment in CNS, Parkinson's Disease, Prevalence Population, Brazil, (Million), 2010-2017
  • Figure 29: Clinical Trial Recruitment in CNS, Parkinson's Disease, Prevalence Population, India, (Million), 2010-2017
  • Figure 30: Clinical Trial Recruitment in CNS, Parkinson's Disease, Prevalence Population, China, (Million), 2010-2017
  • Figure 31: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Patients Recruited by Phase, 2000-2009
  • Figure 32: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Patients Recruited by Sponsor, 2000-2009
  • Figure 33: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Patients Recruited by Geography, (%), 2000-2009
  • Figure 34: Clinical Trial Recruitment in CNS, Parkinson's Disease, Total Number of Patients Recruited per Year, 2000-2009
  • Figure 35: Clinical Trial Recruitment in CNS, Parkinson's Disease, Average Number of Patients Recruited by Stage of Development, 2000-2009
  • Figure 36: Clinical Trial Recruitment in CNS, Parkinson's Disease, Average Number of Patients Recruited per Trial per Year, 2000-2009
  • Figure 37: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Clinical Trials by Phase, 2000-2009
  • Figure 38: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Clinical Trials by Major Sponsors, 2000-2009
  • Figure 39: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Clinical Trials by Geography, (%), 2000-2009
  • Figure 40: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Clinical Trials per Year, 2000-2009
  • Figure 41: Clinical Trial Recruitment in CNS, Epilepsy, Prevalence Population, Brazil, (Million), 2010-2017
  • Figure 42: Clinical Trial Recruitment in CNS, Epilepsy, Prevalence Population, India, (Million), 2010-2017
  • Figure 43: Clinical Trial Recruitment in CNS, Epilepsy, Prevalence Population, China, (Million), 2010-2017
  • Figure 44: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Patients Recruited by Phase, 2000-2009
  • Figure 45: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Patients Recruited by Major Sponsors, 2000-2009
  • Figure 46: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Patients Recruited by Geography , (%), 2000-2009
  • Figure 47: Clinical Trial Recruitment in CNS, Epilepsy, Total Number of Patients Recruited per Year, 2000-2009
  • Figure 48: Clinical Trial Recruitment in CNS, Epilepsy, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2009
  • Figure 49: Clinical Trial Recruitment in CNS, Epilepsy, Average Number of Patients Recruited per Trial per Year, 2000-2009
  • Figure 50: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Clinical Trials by Phase, 2000-2009
  • Figure 51: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Clinical Trials by Major Sponsors, 2000-2009
  • Figure 52: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Clinical Trials by Geography ,(%), 2000-2009
  • Figure 53: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Clinical Trials per Year, 2000-2009
  • Figure 54: Clinical Trial Recruitment in CNS, Schizophrenia, Prevalence Population, Brazil, (Million), 2010-2017
  • Figure 55: Clinical Trial Recruitment in CNS, Schizophrenia, Prevalence Population, India, (Million), 2010-2017
  • Figure 56: Clinical Trial Recruitment in CNS, Schizophrenia, Prevalence Population, China, (Million), 2010-2017
  • Figure 57: Clinical Trial Recruitment bfin CNS, Schizophrenia, Total Number of Patients Recruited by Phase, 2000-2009
  • Figure 58: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Patients Recruited by Major Sponsors, 2000-2009
  • Figure 59: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Patients Recruited by Geography , (%), 2000-2009
  • Figure 60: Clinical Trial Recruitment in CNS, Schizophrenia, Total Number of Patients Recruited per Year, 2000-2009
  • Figure 61: Clinical Trial Recruitment in CNS, Schizophrenia, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2009
  • Figure 62: Clinical Trial Recruitment in CNbfS, Schizophrenia, Average Number of Patients Recruited per Trial per Year, 2000-2009
  • Figure 63: Clinical Trial Recruitment in CNS, Depression, Total Number of Clinical Trials by Phase, 2000-2009
  • Figure 64: Clinical Trial Recrbfuitment in CNS, Depression, Total Number of Clinical Trials by Major Sponsors, 2000-2009
  • Figure 65: Clinical Trial Recruitment in CNS, Depression, Total Number of Clinical Trials by Geography, (%), 2000-2009
  • Figure 66: Clinical Trial Recruitment in CNS, Depression, Total Number of Clinical Trials per Year, 2000-2009
  • Figure 67: Clinical Trial Recruitment in CNS, Depression, Prevalence Population, Brazil, (Million), 2010-2017
  • Figure 68: Clinical Trial Recruitment in CNS, Depression, Prevalence Population, India, (Million), 2010-2017
  • Figure 69: Clinical Trial Recruitment in CNS, Depression, Prevalence Population, China, (Million), 2010-2017
  • Figure 70: Clinical Trial Recruitment in CNS, Depression, Total Number of Patients Recruited by Phase, 2000-2009
  • Figure 71: Clinical Trial Recruitment in CNS, Depression, Total Number of Patients Recruited by Major Sponsors, 2000-2009
  • Figure 72: Clinical Trial Recruitment in CNS, Depression, Total Number of Patients Recruited by Geography, (%), 2000-2009
  • Figure 73: Clinical Trial Recruitment in CNS, Depression, Total Number of Patients Recruited per Year, 2000-2009
  • Figure 74: Clinical Trial Recruitment in CNS, Depression, Average Number of Patients Recruited per Trial by Stage of Development, 2000-2009
  • Figure 75: Clinical Trial Recruitment in CNS, Depression, Average Number of Patients Recruited per Trial per Year, 2000-2009
Back to Top